<DOC>
	<DOCNO>NCT02792231</DOCNO>
	<brief_summary>To compare efficacy safety ofatumumab administer subcutaneously ( sc ) every 4 week versus teriflunomide administer orally daily patient relapse multiple sclerosis</brief_summary>
	<brief_title>Efficacy Safety Ofatumumab Compared Teriflunomide Patients With Relapsing Multiple Sclerosis .</brief_title>
	<detailed_description>This randomize , double-blind , double-dummy , active comparator-controlled , parallel-group , multicenter study variable treatment duration approximately 900 patient relapse MS . The maximal treatment duration study individual patient 2.5 year . Eligible patient randomize receive either experimental ofatumumab subcutaneous ( sc ) injection every 4 week active comparator teriflunomide orally daily . In order blind different formulation , double-dummy masking use i.e . patient take injection ( contain either active ofatumumab placebo ) oral capsule ( contain either active teriflunomide placebo ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis multiple sclerosis ( MS ) Relapsing MS ( RRMS SPMS ) course At least 1 relapse previous 1 year 2 relapse previous 2 year positive gadoliniumenhancing MRI scan previous year EDSS score 0 5.5 Primary progressive MS Disease duration 10 year patient EDSS score 2 less Patients active chronic disease immune system MS Patients risk develop reactivation hepatitis Patients active systemic infection neurological finding consistent PML Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Relapsing multiple sclerosis</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>